Edition:
India

ChemoCentryx Inc (CCXI.OQ)

CCXI.OQ on NASDAQ Stock Exchange Global Select Market

7.27USD
14 Oct 2019
Change (% chg)

$-0.32 (-4.22%)
Prev Close
$7.59
Open
$7.60
Day's High
$7.62
Day's Low
$7.20
Volume
92,155
Avg. Vol
168,633
52-wk High
$14.96
52-wk Low
$6.16

Latest Key Developments (Source: Significant Developments)

Chemocentryx Posts Q2 Revenue Of $7.2 Million Versus $15 Million
Tuesday, 6 Aug 2019 

Aug 5 (Reuters) - ChemoCentryx Inc ::CHEMOCENTRYX REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS AND RECENT HIGHLIGHTS.Q2 REVENUE $7.2 MILLION VERSUS $15 MILLION.Q2 REVENUE ESTIMATE $9.8 MILLION -- REFINITIV IBES DATA.CASH, CASH EQUIVALENTS AND INVESTMENTS TOTALED $223.1 MILLION AT JUNE 30, 2019.QTRLY LOSS PER SHARE $0.26.Q2 EARNINGS PER SHARE VIEW $-0.22 -- REFINITIV IBES DATA.TOPLINE DATA FROM PIVOTAL ADVOCATE PHASE III TRIAL OF C5A RECEPTOR INHIBITOR AVACOPAN IN ANCA VASCULITIS ON TRACK FOR Q4 2019.  Full Article

ChemoCentryx Reports Qtrly Loss Per Share $0.23
Tuesday, 7 May 2019 

May 6 (Reuters) - ChemoCentryx Inc ::CHEMOCENTRYX REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND RECENT HIGHLIGHTS.Q1 REVENUE $8.3 MILLION VERSUS $9.5 MILLION.Q1 REVENUE ESTIMATE $11 MILLION -- REFINITIV IBES DATA.CASH, CASH EQUIVALENTS AND INVESTMENTS TOTALED $234.1 MILLION AT MARCH 31, 2019.COMPANY EXPECTS TO UTILIZE CASH AND INVESTMENTS IN RANGE OF $75.0 MILLION TO $85.0 MILLION IN 2019.QTRLY LOSS PER SHARE $0.23.Q1 EARNINGS PER SHARE VIEW $-0.24, REVENUE VIEW $11.0 MILLION -- REFINITIV IBES DATA.  Full Article

Chemocentryx Posts Qtrly Loss Per Share Of $0.21
Tuesday, 12 Mar 2019 

March 11 (Reuters) - ChemoCentryx Inc ::CHEMOCENTRYX REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND RECENT HIGHLIGHTS.Q4 REVENUE $9.3 MILLION VERSUS REFINITIV IBES ESTIMATE OF $9.4 MILLION.QTRLY LOSS PER SHARE $0.21.EXPECTS TO UTILIZE CASH AND INVESTMENTS IN RANGE OF $75.0 MILLION AND $85.0 MILLION IN 2019.  Full Article

Chemocentryx Announces Proposed Public Offering Of $75 Mln Of Its Common Stock
Thursday, 27 Sep 2018 

Sept 26 (Reuters) - ChemoCentryx Inc ::CHEMOCENTRYX ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.CHEMOCENTRYX INC - COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF $75 MILLION OF ITS COMMON STOCK.  Full Article

Chemocentryx Q4 Revenue $56.3 Million Versus $4.9 Million
Friday, 9 Mar 2018 

March 9 (Reuters) - Chemocentryx Inc ::CHEMOCENTRYX REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND RECENT HIGHLIGHTS.Q4 REVENUE $56.3 MILLION VERSUS $4.9 MILLION.Q4 REVENUE VIEW $9.4 MILLION -- THOMSON REUTERS I/B/E/S.QUARTERLY EARNINGS PER SHARE $0.80.  Full Article

Chemocentryx reports Q3 revenue $9.0 million
Wednesday, 8 Nov 2017 

Nov 7 (Reuters) - Chemocentryx Inc ::Chemocentryx reports third quarter 2017 financial results and recent highlights.Q3 revenue $9.0 million versus I/B/E/S view $9 million.Chemocentryx Inc - ‍expects to utilize cash and cash equivalents in range of $50 million and $55 million in 2017​.Chemocentryx inc - ‍phase iii advocate trial of avacopan remains on track to complete enrollment in mid-2018​.Chemocentryx Inc - ‍plan to launch registration-supporting trial for CCX140 in treatment of focal segmental glomerulosclerosis (FSGS) in Q4 2017​.Chemocentryx Inc - qtrly loss per share $0.13​.  Full Article